Abstract
Background
We sought to evaluate the effectiveness of definitive or adjuvant external-beam proton therapy on local control and survival in patients with skull-base chondrosarcoma.
Methods
We reviewed the medical records of 43 patients with a median age of 49 years (range, 23–80 years) treated with double-scattered 3D conformal proton therapy for skull-base chondrosarcomas between January 2007 and February 2016. Proton therapy-related toxicities were scored using CTCAE v4.0.
Results
The median radiotherapy dose was 73.8 Gy(RBE) (range, 64.5–74.4 Gy[RBE]). Thirty-six (84%) and 7 (16%) patients underwent surgical resection or biopsy alone. Tumor grade distribution included: grade 1, 19 (44%) patients; grade 2, 22 (51%); and grade 3, 2 (5%). Forty patients had gross disease at the time of radiotherapy and 7 patients were treated for locally recurrent disease following surgery. The median follow-up was 3.7 years (range, 0.7–10.1 years). There were no acute grade 3 toxicities related to RT. At 4 years following RT, actuarial rates of overall survival, cause-specific survival, local control, and RT-related grade 3 toxicity-free survival were 95%, 100%, 89%, and 95%.
Conclusion
High-dose, double-scattered 3D conformal proton therapy alone or following surgical resection for skull-base chondrosarcoma is an effective treatment with a high rate of local control with no acute grade 3 radiation-related toxicity. Further follow-up of this cohort is necessary to better characterize long-term disease control and late toxicities.
Similar content being viewed by others
References
Harsh GR, Vaz-Guimaraes F (eds) (2017) Chordomas and chondrosarcomas of the skull base and spine, 2nd edn. Academic Press, Cambridge, MA
Fossati P, Vavassori A, Deantonio L, Ferrara E, Krengli M, Orecchia R (2016) Review of photon and proton radiotherapy for skull base tumours. Rep Pract Oncol Radiother 21(4):336–355
Sahgal A, Chan MW, Atenafu EG, Masson-Cote L, Bahl G, Yu E et al (2015) Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. Neuro-Oncology 17(6):889–894
Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PAS (2019) The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: an analysis of the National Cancer Data Base. Cancer 125(4):642–651
Verdegaal SH, Bovee JV, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC et al (2011) Incidence, predictive factors, and prognosis of chondrosarcoma in patients with ollier disease and maffucci syndrome: an international multicenter study of 161 patients. Oncologist 16(12):1771–1779
Deraniyagala RL, Yeung D, Mendenhall WM, Li Z, Morris CG, Mendenhall NP et al (2014) Proton therapy for skull base chordomas: an outcome study from the university of Florida proton therapy institute. J Neurol Surg B 75(1):53–57
Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH et al (2008) The clinical approach towards chondrosarcoma. Oncologist 13(3):320–329
Bloch OG, Jian BJ, Yang I, Han SJ, Aranda D, Ahn BJ et al (2010) Cranial chondrosarcoma and recurrence. Skull Base 20(3):149–156
Tzortzidis F, Elahi F, Wright DC, Temkin N, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chondrosarcomas. Neurosurgery 58(6):1090–1098
Gay E, Sekhar LN, Rubinstein E, Wright DC, Sen C, Janecka IP et al (1995) Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 36(5):887–896.
Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE et al (1999) Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 23(11):1370–1378
Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP et al (2009) Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol, Biol, Phys 75(4):1111–1118
Feuvret L, Bracci S, Calugaru V, Bolle S, Mammar H, De Marzi L et al (2016) Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol, Biol, Phys 95(1):312–321
Fuji H, Nakasu Y, Ishida Y, Horiguchi S, Mitsuya K, Kashiwagi H et al (2011) Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base. Skull Base 21(3):201–206
Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA et al (1999) Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 91(3):432–439
Weber DC, Murray F, Combescure C, Calugaru V, Alapetite C, Albertini F et al (2018) Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiother Oncol 129:520–526
Weber DC, Malyapa R, Albertini F, Bolsi A, Kliebsch U, Walser M et al (2016) Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 120(1):169–174
Munzenrider JE, Liebsch NJ (1999) Proton therapy for tumors of the skull base. Strahlentherapie und Onkologie 175(Suppl 2):57–63
Grosshans DR, Zhu XR, Melancon A, Allen PK, Poenisch F, Palmer M et al (2014) Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes. Int J Radiat Oncol, Biol, Phys 90(3):540–546
Mattke M, Vogt K, Bougatf N, Welzel T, Oelmann-Avendano J, Hauswald H et al (2018) High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center. Cancer 124(9):2036–2044
Uhl M, Mattke M, Welzel T, Oelmann J, Habl G, Jensen AD et al (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120(10):1579–1585
Li D, Weng JC, Zhang GJ, Hao SY, Tang J, Zhang LW et al (2018) Proposed treatment paradigm for intracranial chondrosarcomas based on multidisciplinary coordination. World Neurosurg 109:e517–e530
Bohman LE, Koch M, Bailey RL, Alonso-Basanta M, Lee JY (2014) Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. World Neurosurg 82(5):806–814
Uhl M, Herfarth K, Debus J (2014) Comparing the use of protons and carbon ions for treatment. Cancer J (Sudbury, Mass). 20(6):433–439
Combs SE, Nikoghosyan A, Jaekel O, Karger CP, Haberer T, Munter MW et al (2009) Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer 115(6):1348–1355
Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, Jakel O et al (2007) Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol, Biol, Phys 67(1):171–177
Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, Jakel O et al (2011) Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol, Biol, Phys 81(5):e793–e801
Terezakis SA, Heron DE, Lavigne RF, Diehn M, Loo BW (2011) Jr. What the diagnostic radiologist needs to know about radiation oncology. Radiology 261(1):30–44
Ballo MT, Chronowski GM, Schlembach PJ, Bloom ES, Arzu IY, Kuban DA (2014) Prospective peer review quality assurance for outpatient radiation therapy. Pract Radiat Oncol 4(5):279–284
Li CS, Vannabouathong C, Sprague S, Bhandari M (2015) The use of carbon-fiber-reinforced (CFR) PEEK material in orthopedic implants: a systematic review. Clin Med Insights Arth Musculoskelet Disord 8:33–45
Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA et al (2015) Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European musculoskeletal oncology society study. Eur J Cancer (Oxford, England: 1990) 51(3):374–381
van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME et al (2018) Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. Oncologist 24:110–116
Acknowledgements
The authors would like to acknowledge Robin Cacchio, and Amanda Prince for research assistance; the CNS cancer nursing team, including Michelle Wear, Lauren Mynatt, and Michelle Myers; and Jessica Kirwan and Christopher Stich for editorial assistance.
Author information
Authors and Affiliations
Contributions
Substantial contributions to the conception or design of the work (ALH, RR, WMM); acquisition, analysis, or interpretation of data for the work (all authors); drafting the work (ALH); revising it critically for important intellectual content (all authors); final approval of the version to be published (all authors).
Corresponding author
Ethics declarations
Conflict of interest
Educational grant from Ion Beam Applications (DI).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Holtzman, A.L., Rotondo, R.L., Rutenberg, M.S. et al. Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. J Neurooncol 142, 557–563 (2019). https://doi.org/10.1007/s11060-019-03129-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03129-8